LL-37 (cathelicidin)
hCAP-18 / CAP-18 C-terminal fragment, cathelicidin antimicrobial peptide (CAMP gene product)
The Ground Truth Score
four plain questions, never one numberReal human trials, but topical, mixed-to-failed, and not for the injected use being sold
Bottom line
LL-37 is a genuine human peptide with actual clinical trials, but the trials were topical wound-healing (the largest one failed its primary endpoint) and small-scale intratumoral cancer injections, none support the systemic subcutaneous "immune/gut/Lyme" use vendors market, and its own biology flags it as a driver of clotting, atherosclerosis, and autoimmunity.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported (NOT prescribed) from vendor/clinic guides, which are not clinical sources: subcutaneous, roughly 100-300 mcg per day, sometimes split AM/PM, 5 days/week for a 4-6 week course; conservative users titrate from ~100-150 mcg and increase ~50 mcg every 1-2 weeks.
Reported, not prescribed. Verify your vial and your math.
First documented human use
First documented controlled human use was a 2014 first-in-man, placebo-controlled trial of TOPICAL synthetic LL-37 on hard-to-heal venous leg ulcers (Gronberg et al., Wound Repair Regen, 34 patients). Intratumoral injection into melanoma metastases followed in a small phase-1 program (ClinicalTrials.gov NCT02225366; a published case describes an 8-week weekly intratumoral course). No completed controlled human trial exists for the systemic subcutaneous "wellness/immune/anti-aging" use that gray-market vendors promote, for that route the honest answer is: no controlled human trial has been completed.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- Marketed as a broad-spectrum antimicrobial/anti-biofilm peptide for chronic or stealth infections (commonly Lyme and gut dysbiosis)
- Promoted as an immune modulator that bridges innate and adaptive immunity
- Sold for wound healing, gut-lining repair, and general recovery
- Some vendors pitch it as an anti-cancer or anti-inflammatory agent based on lab and animal data
The data behind each bullet
What actually backs it
LL-37 is the only human cathelicidin and has direct, broad antimicrobial and anti-biofilm activity in vitro against many bacteria, fungi, and viruses (~1 uM range).
Extensive in-vitro and mechanistic literature; this is lab-dish activity, not demonstrated clinical antimicrobial benefit in people.
PubMed: LL-37 antimicrobial mechanism ↗Topical LL-37 improved healing of hard-to-heal venous leg ulcers in a first-in-man, placebo-controlled trial (lower doses healed several-fold faster than placebo).
Single small randomized placebo-controlled first-in-man trial, n=34, topical route, dose-response signal at lower concentrations.
PubMed PMID 25041740 (Gronberg 2014) ↗In a larger phase IIb trial (HEAL LL-37, ~148 patients), topical LL-37 did NOT beat placebo for venous-leg-ulcer closure overall.
Larger multicentre randomized placebo-controlled trial; primary endpoint negative (~25% closure in all arms incl. placebo); only a post-hoc large-wound subgroup signalled benefit.
PubMed: HEAL LL-37 phase IIb venous leg ulcer ↗Intratumoral LL-37 injection is being explored for melanoma skin metastases and can stimulate an anti-tumor immune response.
Small early-phase/case-level human work (NCT02225366) plus preclinical data; not powered efficacy.
ClinicalTrials.gov NCT02225366 ↗Intratumoral LL-37 caused notable dermatologic toxicity (keratoacanthoma-like atypical squamous lesions and bullae) that resolved after stopping.
Published single-patient clinicopathologic case report from the melanoma program; lesions appeared ~45 days in, cleared within 2 months of cessation.
PubMed PMID 29665030 ↗Systemic subcutaneous LL-37 for immune support, Lyme/biofilm, or gut healing has clinical benefit.
No completed controlled human trial for this route or indication; claims rest on vendor/clinic marketing, in-vitro data, and anecdote.
PubMed: LL-37 Lyme / systemic human (none found) ↗Elevated/exogenous LL-37 is mechanistically implicated as a DRIVER of disease: it primes platelets and promotes arterial thrombosis, aggravates atherosclerotic plaque, and is an autoantigen in lupus and psoriasis.
Consistent animal and human-tissue/ex-vivo mechanistic evidence; LL-37 abundant in coronary thrombi, T-cells reactive to LL-37 in ~45% of lupus patients, self-DNA/LL-37 complexes drive interferon.
PubMed: LL-37 platelet thrombosis atherosclerosis lupus ↗Mechanism
How it's assumed to work
Assumed/theoretical. LL-37 is the active C-terminal fragment of human hCAP-18, cleaved (e.g., by proteinase-3) into a 37-residue cationic amphipathic peptide. Its assumed direct action is membrane disruption, it binds anionic microbial membranes, oligomerizes, and forms pores/extracts lipids, killing bacteria, fungi, and some viruses and disrupting biofilms in vitro. Its assumed immunomodulatory action is via receptors like FPR2/FPRL1 and scavenger/Toll-like receptors: it chemoattracts immune cells, neutralizes LPS, and, when complexed with self nucleic acids, activates plasmacytoid dendritic cells to produce type-I interferon (the same pathway that makes it a double-edged autoimmunity driver). It is not an approved drug, so all of this is mechanism, not proven clinical effect.
Dosing & handling
What users and clinicians report
Reported (NOT prescribed) from vendor/clinic guides, which are not clinical sources: subcutaneous, roughly 100-300 mcg per day, sometimes split AM/PM, 5 days/week for a 4-6 week course; conservative users titrate from ~100-150 mcg and increase ~50 mcg every 1-2 weeks. Clinical trial dosing was entirely different in route and form, topical 0.5-3.2 mg/mL applied to wound beds, or direct intratumoral injection, and does not validate any systemic subcutaneous regimen.
These numbers are marketing-derived, not evidence-based. There is no established safe or effective human dose for subcutaneous LL-37, no dose-finding study for that route, and the mechanistic harm signals (platelet/clotting, autoimmune, pro-tumor in some tissues) mean "more is better" is actively unsafe reasoning. Verify the vial's stated mg before any dose math, and recognize that a number being printed on a vendor PDF does not make it validated.
Timing & food
Reported timing is generally a daily subcutaneous dose, sometimes split morning/evening, with no strong food/fasted rationale. LL-37 acts locally/systemically on cells and membranes rather than through a metabolic or nutrient-timed pathway, so meal timing is not mechanistically meaningful. Some users rotate injection sites (abdomen, thigh, upper arm). None of this timing is trial-validated; it is convention copied across vendor guides.
Half-life
Very short, minutes in unprotected biological fluids/serum, due to rapid cleavage by host serine proteases (kallikreins, elastase, trypsin-like enzymes) and serum-binding factors. It is more stable topically in wound exudate, which is part of why the credible human data are topical. This short systemic half-life undercuts the rationale for infrequent subcutaneous dosing.
Reconstitution sensitivity
Lyophilized powder; vendors advise storage frozen (around -20C or colder) before reconstitution. Reconstitute with bacteriostatic water and add the liquid gently down the vial wall, swirl/roll, never shake, as agitation/foaming can degrade the peptide. As a highly cationic membrane-active peptide it can adsorb to surfaces and is degradation-prone. Once reconstituted, refrigerate (2-8C) and use within ~2 weeks; aliquot and freeze for longer storage and avoid repeated freeze-thaw. Protect from heat and light.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Low. Independent, credible community/forum experience reports for the injectable form are sparse; most of the visible online content is vendor, compounding-clinic, and wellness-blog marketing rather than peer user reports. Lyme and chronic-illness forums mention it but with little detailed first-hand dosing-and-outcome reporting.
Consistency
Mixed and hard to read. Where users do report, accounts split between "felt immune/gut improvement" and "noticed nothing," with effects that are subjective and easily attributable to co-administered antibiotics, herbals, or the natural course of chronic infection. No consistent, distinctive, objective effect emerges from anecdote.
Source credibility
Low. The bulk of positive sentiment originates from sources with a commercial interest in selling the peptide (vendors, peptide clinics, affiliate blogs), which are discounted. Genuinely independent, verifiable user reports are thin, so the real-world signal cannot be weighted as meaningful support.
- Anecdote, not proof: Lyme and chronic-infection users describe trying it for biofilm/'stealth pathogen' support, with some reporting a sense of improved immune resilience or fewer flares and others reporting no discernible change.
- Some users of the subcutaneous form report injection-site redness, swelling, or transient flu-like feelings in the first days.
- Gut-focused users anecdotally pair it with diet/probiotic changes and credit improved digestion, though attribution is muddy.
- A recurring theme even among enthusiasts is uncertainty about whether anything is happening, given the absence of an objective marker and the peptide's short half-life.
Placebo risk, High
The marketed benefits, "immune support," more energy, gut comfort, feeling better against a chronic/stealth infection, are subjective, slow, and fluctuating endpoints with no objective home readout. They are exactly the kind of outcomes that respond to expectation, to the natural relapsing-remitting course of conditions like Lyme, and to whatever else is being taken at the same time. With no measurable marker the user can check, attribution to LL-37 is unreliable, hence High placebo risk.
Risk panel
What could go wrong
Adverse events
In topical wound trials LL-37 was well tolerated (mild-to-moderate local reactions; serious adverse events rare and judged unrelated). The standout injected-route signal is from the melanoma program: intratumoral injection produced eruptive keratoacanthoma-like atypical squamous lesions and a vesiculo-bullous reaction that mimicked malignancy, resolving ~2 months after stopping. Common reported local effects of subcutaneous use are injection-site redness/swelling and flu-like symptoms.
Theoretical concerns
This is the central concern and why safety is graded low despite "endogenous" framing. Raising LL-37 systemically engages the same biology that, when overexpressed, is implicated in harm: it primes platelets via GPVI and augments arterial thrombus formation; LL-37/mitochondrial-DNA complexes aggravate atherosclerotic lesions; it is a NETosis component tied to thrombosis on coronary plaques; and bound to self-DNA/RNA it acts as an autoantigen and interferon trigger central to lupus, psoriasis, and rosacea pathophysiology. Its role in cancer is dual and tissue-specific, pro-tumor in ovarian, lung, and breast models, so "anti-cancer peptide" is an oversimplification.
Contraindications
Theoretical caution flags (not formal label contraindications, since there is no approved systemic product): active or high-risk cardiovascular/atherosclerotic disease and clotting/platelet disorders; autoimmune disease, especially lupus, psoriasis, or rosacea, where LL-37 is implicated as a driver; and personal history of cancers where LL-37 is pro-tumor. Pregnancy/breastfeeding untested. Anyone on antiplatelet/anticoagulant therapy should treat the thrombosis-priming data as a real interaction concern.
Honest unknowns
No human data on long-term systemic subcutaneous dosing, the route and indication most people buy it for are essentially untested in controlled trials. Unknown whether exogenous dosing meaningfully raises tissue LL-37 long enough to matter (it is degraded within minutes in serum), and unknown whether chronic elevation tips the cardiovascular/autoimmune/oncologic risk biology in real users. Gray-market product purity, endotoxin load, and actual peptide content are unverified.
Confound watch
In the communities using it, LL-37 is rarely run alone. Lyme/chronic-infection users typically stack antibiotics, herbal antimicrobials, binders, and other peptides (BPC-157, thymosin alpha-1, KPV); gut users add probiotics and diet changes; recovery users stack BPC-157/TB-500 and improved sleep. Any perceived antimicrobial or immune benefit is heavily confounded by concurrent antibiotics, the natural waxing/waning of chronic illness, and regression to the mean.
History
Discovery → first use → status
Heads up: the legal status is moving (2026)
This one got put on the FDA's Category 2 'do not compound' list back in 2023. In April 2026 the FDA moved to pull it back off that list, and there's a July 2026 advisory meeting weighing whether it can be legally compounded again. None of that is final, and none of it makes anything proven or safe. It just means the legal picture is changing fast, so check the date on anything you read about whether this is allowed.
FDA peptide compounding update, 2026 ↗- 1995Human cathelicidin (hCAP-18) and its C-terminal LL-37 fragment first identified/characterized.
- 2014First-in-man placebo-controlled trial of topical LL-37 on venous leg ulcers (n=34), positive dose-response signal at lower doses.
- 2014-2018Phase-1 intratumoral LL-37 program in melanoma skin metastases (NCT02225366); published case documents dermatologic toxicity from weekly injections.
- 2021Larger phase IIb HEAL LL-37 venous-leg-ulcer trial (~148 patients) reports negative primary endpoint, no benefit over placebo overall.
- 2020sMarketed by compounding pharmacies and longevity/wellness clinics as an injectable antimicrobial/immune peptide despite absence of supportive systemic human trials.
Verification
The COA standard, applied
Grades reflect: (a) real but route-mismatched human trials, topical venous-leg-ulcer RCTs (one positive first-in-man n=34, one negative phase IIb n~148) and a small intratumoral melanoma program; (b) no completed controlled human trial for systemic subcutaneous use; (c) a documented injection-route toxicity case; and (d) a substantial mechanistic harm literature (thrombosis, atherosclerosis, lupus/psoriasis autoimmunity, dual cancer role). Citations are PubMed search URLs, two specific resolvable PMIDs (25041740, 29665030), and a ClinicalTrials.gov study ID (NCT02225366). No PMIDs, titles, authors, or statistics were invented; where evidence is thin it is labeled thin.
The full verification standard →Sources
Where this comes from
- Gronberg 2014, first-in-man topical LL-37 venous leg ulcer RCT (PMID 25041740) ↗· Small positive first-in-human trial; topical route; dose-response at lower concentrations.
- HEAL LL-37 phase IIb venous leg ulcer trial (PubMed search) ↗· Larger ~148-patient RCT; NEGATIVE primary endpoint, no benefit vs placebo overall.
- Dermatologic toxicity of intratumoral LL-37 in melanoma (PMID 29665030) ↗· Case report: keratoacanthoma-like lesions/bullae from weekly injections, resolved on stopping.
- ClinicalTrials.gov NCT02225366, intratumoral LL-37 for melanoma ↗· Early-phase intratumoral injection study; the injectable human-use anchor.
- LL-37 platelet/thrombosis/atherosclerosis/lupus harm biology (PubMed search) ↗· Mechanistic evidence LL-37 drives clotting, plaque, and autoimmunity, basis for the low safety grade.
- LL-37 antimicrobial mechanism & membrane action (PubMed search) ↗· In-vitro/mechanistic basis for the antimicrobial and immunomodulatory claims.
- LL-37 stability / proteolytic degradation (PMID 21547341) ↗· Documents rapid degradation/short half-life and relative stability in wound exudate.
- LL-37 in cancer, dual pro/anti-tumor role (PubMed search) ↗· Tissue-specific; pro-tumor in ovarian/lung/breast, tempers 'anti-cancer' marketing.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.